ES2703324T3 - Identificación de mutaciones de canalrodopsina-2 (Chop2) y métodos de uso - Google Patents
Identificación de mutaciones de canalrodopsina-2 (Chop2) y métodos de uso Download PDFInfo
- Publication number
- ES2703324T3 ES2703324T3 ES13710253T ES13710253T ES2703324T3 ES 2703324 T3 ES2703324 T3 ES 2703324T3 ES 13710253 T ES13710253 T ES 13710253T ES 13710253 T ES13710253 T ES 13710253T ES 2703324 T3 ES2703324 T3 ES 2703324T3
- Authority
- ES
- Spain
- Prior art keywords
- cell
- chop2
- seq
- light
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 34
- 230000035772 mutation Effects 0.000 title description 39
- 235000001014 amino acid Nutrition 0.000 claims abstract description 79
- 229920001184 polypeptide Polymers 0.000 claims abstract description 63
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 63
- 150000001413 amino acids Chemical group 0.000 claims abstract description 25
- 235000018417 cysteine Nutrition 0.000 claims abstract description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 19
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 120
- 210000003994 retinal ganglion cell Anatomy 0.000 claims description 46
- 230000004438 eyesight Effects 0.000 claims description 44
- 230000000007 visual effect Effects 0.000 claims description 41
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 30
- 102000039446 nucleic acids Human genes 0.000 claims description 30
- 206010034960 Photophobia Diseases 0.000 claims description 27
- 208000013469 light sensitivity Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 27
- 108091008695 photoreceptors Proteins 0.000 claims description 19
- 210000000411 amacrine cell Anatomy 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 15
- 210000002287 horizontal cell Anatomy 0.000 claims description 12
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 210000000857 visual cortex Anatomy 0.000 claims description 8
- 208000022873 Ocular disease Diseases 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 208000030533 eye disease Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 206010047531 Visual acuity reduced Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 67
- 108090000623 proteins and genes Proteins 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 108091006146 Channels Proteins 0.000 description 35
- 210000001525 retina Anatomy 0.000 description 30
- 230000004044 response Effects 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 23
- 230000002207 retinal effect Effects 0.000 description 21
- 201000004569 Blindness Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000008062 neuronal firing Effects 0.000 description 17
- 210000000608 photoreceptor cell Anatomy 0.000 description 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 15
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 15
- 239000004473 Threonine Substances 0.000 description 15
- 208000003098 Ganglion Cysts Diseases 0.000 description 13
- 208000005400 Synovial Cyst Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 12
- 210000001508 eye Anatomy 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 11
- 230000002123 temporal effect Effects 0.000 description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 210000001116 retinal neuron Anatomy 0.000 description 10
- 241000195597 Chlamydomonas reinhardtii Species 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 108050001704 Opsin Proteins 0.000 description 7
- 230000028161 membrane depolarization Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 102000010175 Opsin Human genes 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102100040756 Rhodopsin Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000023077 detection of light stimulus Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000004393 visual impairment Effects 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005670 electromagnetic radiation Effects 0.000 description 3
- 230000004298 light response Effects 0.000 description 3
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 230000016732 phototransduction Effects 0.000 description 3
- 230000001179 pupillary effect Effects 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 3
- 230000004296 scotopic vision Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101100275320 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) COP4 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710131038 Opsin-2 Proteins 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 230000002060 circadian Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 229910052724 xenon Inorganic materials 0.000 description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 206010005176 Blindness congenital Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 101710111837 Cyclic phosphodiesterase Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100025912 Melanopsin Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100135809 Mus musculus Pcp2 gene Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000010221 calcium permeability Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000006623 congenital stationary night blindness Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 206010011005 corneal dystrophy Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000575 glycinergic effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001926 inhibitory interneuron Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010005417 melanopsin Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000003977 optic chiasm Anatomy 0.000 description 1
- 210000005112 optic tract Anatomy 0.000 description 1
- 230000004421 optic tracts Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004466 optokinetic reflex Effects 0.000 description 1
- 101150037969 pde-6 gene Proteins 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000013608 rAAV vector Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000025474 response to light stimulus Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000002645 vision therapy Methods 0.000 description 1
- 230000003945 visual behavior Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606663P | 2012-03-05 | 2012-03-05 | |
| PCT/US2013/029171 WO2013134295A1 (en) | 2012-03-05 | 2013-03-05 | Identification of channelrhodopsin-2 (chop2) mutations and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2703324T3 true ES2703324T3 (es) | 2019-03-08 |
Family
ID=47892055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13710253T Active ES2703324T3 (es) | 2012-03-05 | 2013-03-05 | Identificación de mutaciones de canalrodopsina-2 (Chop2) y métodos de uso |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10947281B2 (enExample) |
| EP (1) | EP2822964B1 (enExample) |
| JP (3) | JP6395611B2 (enExample) |
| KR (1) | KR102137717B1 (enExample) |
| CN (2) | CN111378020A (enExample) |
| AU (4) | AU2013230112A1 (enExample) |
| CA (1) | CA2866405A1 (enExample) |
| DK (1) | DK2822964T3 (enExample) |
| EA (1) | EA201491643A1 (enExample) |
| ES (1) | ES2703324T3 (enExample) |
| HU (1) | HUE040487T2 (enExample) |
| MX (1) | MX360085B (enExample) |
| NZ (1) | NZ629843A (enExample) |
| PL (1) | PL2822964T3 (enExample) |
| PT (1) | PT2822964T (enExample) |
| WO (1) | WO2013134295A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470790B2 (en) | 2006-05-04 | 2013-06-25 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| US9453241B2 (en) | 2010-05-04 | 2016-09-27 | Wayne State University | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| CN111378020A (zh) | 2012-03-05 | 2020-07-07 | 韦恩州立大学 | 通道视蛋白-2(Chop2)突变的鉴定及使用方法 |
| WO2014160281A2 (en) | 2013-03-14 | 2014-10-02 | Wayne State University | Method of enhancing delivery of therapeutic compounds to the eye |
| US10234761B2 (en) | 2013-07-08 | 2019-03-19 | Basf Se | Oxime ester photoinitiators |
| WO2015138616A1 (en) | 2014-03-11 | 2015-09-17 | Wayne State University | A modified mglur6 promoter and methods of use |
| KR20230160967A (ko) | 2016-05-03 | 2023-11-24 | 웨인 스테이트 유니버시티 | 프로테오좀 억제제를 사용하여 눈에서 바이러스 매개 유전자 전달을 향상시키는 방법 |
| JP2019522469A (ja) * | 2016-06-03 | 2019-08-15 | マックス−プランク−ゲゼルシャフト ツア フェルデルンク デア ヴィッセンシャフテン エー．ファウ． | チャネルロドプシンの変異型光誘導性イオンチャネル |
| RU2019109021A (ru) * | 2016-08-29 | 2020-09-29 | Уэйн Стейт Юниверсити | Идентификация мутаций в вариантах каналопсина, имеющих улучшенную чувствительность к свету, и способы их применения |
| WO2018106369A2 (en) * | 2016-11-06 | 2018-06-14 | Nanoscope Technologies Llc | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
| WO2018189247A1 (en) * | 2017-04-12 | 2018-10-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | New optogenetic tool |
| SG11202004940VA (en) * | 2017-12-04 | 2020-06-29 | Salvat Lab Sa | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |
| JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
| WO2024226667A2 (en) * | 2023-04-24 | 2024-10-31 | Nanoscope Therapeutics Inc. | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4498919A (en) | 1983-10-31 | 1985-02-12 | Corning Glass Works | Method for making colored photochromic prescription ophthalmic lenses |
| US6610287B1 (en) | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| EP0977880A2 (en) | 1997-04-21 | 2000-02-09 | University Of Florida | Materials and methods for treatment of retinal diseases |
| WO2000015822A1 (en) | 1998-09-17 | 2000-03-23 | University Of Florida | Methods for treatment of degenerative retinal diseases |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION |
| WO2003016486A2 (en) | 2001-08-16 | 2003-02-27 | Sloan Kettering Institute For Cancer Research | Bio-synthetic photostimulators and methods of use |
| DE10216005A1 (de) | 2002-04-11 | 2003-10-30 | Max Planck Gesellschaft | Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle |
| WO2004009022A2 (en) | 2002-07-18 | 2004-01-29 | The General Hospital Corp. | Method for augmenting vision in persons suffering from photoreceptor cell degeneration |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| JP2007527738A (ja) | 2003-11-05 | 2007-10-04 | ニューロヴィジョン， インコーポレイテッド | 視覚を改善するための方法および装置 |
| US20070053996A1 (en) | 2005-07-22 | 2007-03-08 | Boyden Edward S | Light-activated cation channel and uses thereof |
| US8470790B2 (en) * | 2006-05-04 | 2013-06-25 | Wayne State University | Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| US9453241B2 (en) | 2010-05-04 | 2016-09-27 | Wayne State University | AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells |
| SI2614079T1 (sl) * | 2010-09-08 | 2015-10-30 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Mutantski kanalnirodopsin 2 |
| CN111378020A (zh) * | 2012-03-05 | 2020-07-07 | 韦恩州立大学 | 通道视蛋白-2(Chop2)突变的鉴定及使用方法 |
| KR101639859B1 (ko) * | 2014-03-06 | 2016-07-14 | 포항공과대학교 산학협력단 | 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법 |
-
2013
- 2013-03-05 CN CN202010025519.0A patent/CN111378020A/zh active Pending
- 2013-03-05 MX MX2014010664A patent/MX360085B/es active IP Right Grant
- 2013-03-05 US US14/383,211 patent/US10947281B2/en active Active
- 2013-03-05 HU HUE13710253A patent/HUE040487T2/hu unknown
- 2013-03-05 ES ES13710253T patent/ES2703324T3/es active Active
- 2013-03-05 WO PCT/US2013/029171 patent/WO2013134295A1/en not_active Ceased
- 2013-03-05 DK DK13710253.9T patent/DK2822964T3/en active
- 2013-03-05 EP EP13710253.9A patent/EP2822964B1/en active Active
- 2013-03-05 JP JP2014561051A patent/JP6395611B2/ja active Active
- 2013-03-05 EA EA201491643A patent/EA201491643A1/ru unknown
- 2013-03-05 KR KR1020147027985A patent/KR102137717B1/ko active Active
- 2013-03-05 PT PT13710253T patent/PT2822964T/pt unknown
- 2013-03-05 NZ NZ629843A patent/NZ629843A/en unknown
- 2013-03-05 PL PL13710253T patent/PL2822964T3/pl unknown
- 2013-03-05 CA CA2866405A patent/CA2866405A1/en active Pending
- 2013-03-05 CN CN201380022635.5A patent/CN104334575A/zh active Pending
- 2013-03-05 AU AU2013230112A patent/AU2013230112A1/en not_active Abandoned
-
2017
- 2017-10-06 AU AU2017239601A patent/AU2017239601B2/en active Active
-
2018
- 2018-04-23 JP JP2018082403A patent/JP2018134098A/ja not_active Withdrawn
-
2019
- 2019-07-01 JP JP2019123061A patent/JP2019193656A/ja active Pending
- 2019-08-14 AU AU2019216638A patent/AU2019216638B2/en active Active
-
2021
- 2021-03-15 US US17/202,064 patent/US20220033449A1/en not_active Abandoned
- 2021-10-07 AU AU2021245195A patent/AU2021245195B2/en active Active
-
2024
- 2024-04-18 US US18/639,381 patent/US20250066431A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2703324T3 (es) | Identificación de mutaciones de canalrodopsina-2 (Chop2) y métodos de uso | |
| ES2538468T3 (es) | Vectores para la administración de proteínas sensibles a la luz y métodos para su utilización | |
| ES2660114T3 (es) | Canalrodopsinas para el control óptico de células | |
| JP6594854B2 (ja) | 行動状態の光遺伝学的制御方法 | |
| JP2009536219A (ja) | ロドプシン拡散のインビボ送達による視覚応答の回復 | |
| CN110267673B (zh) | 利用chrimson来进行光遗传视觉恢复 | |
| US20230159609A1 (en) | G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd) | |
| JP6779546B2 (ja) | 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途 | |
| EA043449B1 (ru) | ИДЕНТИФИКАЦИЯ МУТАЦИЙ КАНАЛ-ОПСИНА-2 (Chop2) И СПОСОБЫ ПРИМЕНЕНИЯ | |
| HK1205744B (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| US20230338581A1 (en) | G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd) | |
| NZ727041B2 (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| WO2024226667A2 (en) | Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof | |
| Tochitsky | Photochemical control of neuronal activity: methods and clinical application | |
| Munckton | Design and use of a light-gated potassium channel |